Viromed Medical AG (XTER:VME) Other Long-Term Liabilities: €1.37 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:VME Viromed Medical AG XTER:VME
22 GF Score
Price €6.00
! 2 Warning Signs
View Full Analysis

What is Viromed Medical AG Other Long-Term Liabilities?

Viromed Medical AG XTER:VME -5.51% 22 Other Long-Term Liabilities is €1.37 Mil as of Dec. 2025. GuruFocus rates XTER:VME with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Viromed Medical AG's other long-term liabilities for the quarter that ended in Dec. 2025 was €1.37 Mil.

Viromed Medical AG's quarterly other long-term liabilities declined from Dec. 2024 (€1.27 Mil) to Jun. 2025 (€0.02 Mil) but then increased from Jun. 2025 (€0.02 Mil) to Dec. 2025 (€1.37 Mil).

Viromed Medical AG's annual other long-term liabilities increased from Dec. 2023 (€0.16 Mil) to Dec. 2024 (€1.27 Mil) and increased from Dec. 2024 (€1.27 Mil) to Dec. 2025 (€1.37 Mil).

Viromed Medical AG Other Long-Term Liabilities Related Terms

Viromed Medical AG Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Viromed Medical AG's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viromed Medical AG Other Long-Term Liabilities Chart

Viromed Medical AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
0.00 0.03 0.16 1.27 1.37

Viromed Medical AG Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only 0.16 0.01 1.27 0.02 1.37
XTER:VME
22GF Score
Viromed Medical AG XTER:VME
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viromed Medical AG Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of €1.37 Mil mean?
Viromed Medical AG (XTER:VME) has a Other Long-Term Liabilities of €1.37 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Viromed Medical AG and its competitors.
Is Viromed Medical AG's Other Long-Term Liabilities too high?
Viromed Medical AG's current Other Long-Term Liabilities is €1.37 Mil. Overall, Viromed Medical AG has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Viromed Medical AG's Other Long-Term Liabilities compare to ABT and SYK?
Viromed Medical AG's Other Long-Term Liabilities of €1.37 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Medical Devices & Instruments company?
A good Other Long-Term Liabilities depends on the Medical Devices & Instruments industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Viromed Medical AG and its competitors. Viromed Medical AG's current Other Long-Term Liabilities is €1.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viromed Medical AG stock overvalued right now?
Viromed Medical AG (XTER:VME) has a current Other Long-Term Liabilities of €1.37 Mil. The current Other Long-Term Liabilities is €1.37 Mil. Viromed Medical AG's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Viromed Medical AG (XTER:VME), the current Other Long-Term Liabilities is €1.37 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viromed Medical AG Business Description

Other Exchanges VME:GermanyVME:Germany
Address Hauptstrasse 105, Rellingen, Pinneberg, SH, DEU, 25462
Viromed Medical AG is a medical technology company. It focuses on using cold plasma technology to develop medical solutions that protect people from viruses, bacteria, and multi-resistant germs. Viromed's product offerings include ViroCAP, a medical device based on cold plasma technology for treating wounds; ViroCAP derma-podo, a medical device that uses cold atmospheric plasma therapy for skin and foot care; and a Raumluftentkeimer. The company covers the entire value chain from research and development to production, logistics, marketing, and sales of its products.
22GF Score

Get the complete analysis for XTER:VME

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.00
Price